Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 12/20 | 0.67 |
| ▸ | ESR1 | P03372 | 5/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746209 | 0.90 | ESRRG (0.66) | ESRRGESR1ESR2TP53MAPT | |
| SCHEMBL20764036 | 0.81 | ESRRG (1.00) | ESRRGESR1ESR2TP53MAPT | |
| SCHEMBL20764351 | 0.79 | ESRRG (0.67) | ESRRGESR1ESR2TP53HSD17B1 | |
| SCHEMBL20746254 | 0.78 | FYN (0.49) | ESRRGESR1ESR2TP53MAPT | |
| SCHEMBL20746117 | 0.77 | HPGD (0.52) | ESRRGESR1ESR2TP53MAPT | |
| SCHEMBL20764225 | 0.76 | ESRRG (0.64) | ESRRGESR1MAPTNPC1RAB9A | |
| SCHEMBL20764010 | 0.76 | ESRRG (0.91) | ESRRGESR1ESR2TP53MAPT | |
| SCHEMBL17731911 | 0.75 | MEN1 (0.69) | ESRRGTP53MAPTCYP3A4NPC1 | |
| SCHEMBL20764057 | 0.72 | ESRRG (0.76) | ESRRGESR1ESR2TP53MAPT | |
| SCHEMBL5048822 | 0.71 | HDAC6 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795162-B2 | Modulators of the estrogen-related receptor | SAINT LOUIS UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| US-20200247792-A1 | ERR INVERSE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2019036562-A1 | ERR INVERSE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247792-A1 | ERR INVERSE AGONISTS | ESRRA, ESRRB, ESR2 | ESRRG 4/4885ESR1 6/4885ESR2 3/4885 |
| US-11795162-B2 | Modulators of the estrogen-related receptor | ESR2, GPER1, ESRRG | ESRRG 3/4885ESR1 4/4885ESR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.